Expand VRDN Menu
VRDN MENU

VRDN Latest Press Releases

-- January 8, 2026 --

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:01 PM

-- January 6, 2026 --

Viridian Therapeutics Prepares for Transformational 2026 Business Wire 7:01 AM

-- December 22, 2025 --

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease Business Wire 7:00 AM

-- December 5, 2025 --

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:00 AM

-- November 7, 2025 --

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:00 AM

-- November 5, 2025 --

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Business Wire 7:01 AM

-- November 3, 2025 --

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease Business Wire 7:01 AM

-- October 21, 2025 --

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock Business Wire 11:24 PM
Viridian Therapeutics Announces Proposed Underwritten Public Offering Business Wire 4:01 PM

-- October 20, 2025 --

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million Business Wire 7:30 AM

-- October 2, 2025 --

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:00 PM

-- September 15, 2025 --

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates Business Wire 7:01 AM
Market Data Delayed 15 Minutes